Venture Capital Access Online | The eMarketplace for the Venture Capital Industry

 

Bookmark and Share   

Home

Marketplace
Database
News
Store
Resources
Contact Us

 

 

 

News

 

Venture Capital Database 2017 Now Available!

SK Capital Announces Agreement to Acquire Perrigo Company plc’s Active Pharmaceutical Ingredients Business

NEW YORK, August 10, 2017-- SK Capital, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, announced that it has signed a definitive agreement to acquire Perrigo API (the “Business”), Perrigo Company plc’s (NYSE; TASE: PRGO) active pharmaceutical ingredients (“API”) business. As part of the transaction, the parties have agreed to enter into a long-term supply agreement for Perrigo API to supply multiple existing commercial and pipeline APIs to Perrigo. The transaction is expected to close during Q4 2017, before which a new trade name will be selected and announced for the Business.

Perrigo API is a leading developer and manufacturer of generic APIs and finished dose forms (“FDF”) with operations primarily located in Israel and supporting functions in the U.S. and India. The Business has a global customer base and a broad array of products that leverage its specialized manufacturing capabilities and core competency in complex chemistries. Perrigo API is known for its uncompromising commitment to the highest quality and reliability standards and has an exemplary compliance track record.

SK Capital has effectively executed numerous prior transactions by collaborating with management to significantly grow revenue and profitability. This acquisition complements other leading companies that SK owns and operates in the API and FDF value chain including Noramco, Tasmanian Alkaloids and Halo Pharmaceutical, all of which will continue to operate independently post-acquisition.

Commenting on the agreement to acquire Perrigo API, Aaron Davenport, Managing Director at SK Capital, said, “Perrigo API is a proven industry leader with strong innovation and manufacturing capabilities and a quality and customer-centric culture. The skills and expertise of the leadership team, dedicated employee-base and the quality of the manufacturing facilities have enabled the Business to establish a strong market position.”

As part of Perrigo API’s renewed strategic vision to become an independent, high quality API supplier of choice for the generic pharmaceutical industry, four highly-experienced Israeli pharmaceutical executives will be joining the Board of Directors of the Business in partnership with SK Capital: Itzhak Krinsky, Meron Mann, Iftach Seri and Arik Yaari. These executives bring decades of experience managing pharmaceutical businesses of significant scale and complexity, including various roles as executives with Teva Pharmaceutical, Sun Pharma and other leading industry organizations.

Iftach Seri, incoming member of Perrigo API’s Board of Directors, added, “We believe tremendous value can be created through further investments in people, company culture, processes and technologies. We look forward to collaborating with the management team and employees to support their continued growth and building a successful working relationship with Perrigo through our long-term supply agreement.”

RBC Capital Markets LLC and Rothschild acted as SK Capital’s joint buyside advisors, and Kirkland & Ellis LLP and Meitar Liquornik Geva Leshem Tal acted as SK’s legal advisors.

About SK Capital

SK Capital is a private investment firm with a disciplined focus on the specialty materials, chemicals and pharmaceuticals sectors. The firm’s purpose is to build strong and growing businesses that create substantial long-term economic value. SK utilizes its industry, operating and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth and profitability as well as lower operating risk. SK’s portfolio of businesses generates revenues of approximately $6 billion annually, employs more than 8,700 people globally and operates more than 60 plants in 25 countries. The firm currently has approximately $1.9 billion of assets under management. For more information, please visit www.skcapitalpartners.com

Contact:
BackBay Communications
Philip Nunes, 617-391-0792
phil.nunes@backbaycommunications.com


News Index

Venture Capital Database 

 

 NEWS

Latest VC News
VC News Archive
News Search
RSS News Feed

List Your Firm

Entrepreneurs
Investors
Advisors

Venture Capital Database

VCPro Database
Download Trial
Buy Now

VC Tools

VC Pitch
Private Placement Memorandum

Business Plan Tools

Free Business Plan Template
Business Plan Tools

 

 

Copyright © 1998-2017 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer